Study population
| Characteristics . | No. of patients . | |
|---|---|---|
| TX1 . | TX2 . | |
| Median age in years (range) | 51 (29-64) | 52 (32-60) |
| Sex (M/F) | 20/15 | 30/17 |
| Tumor stage | ||
| I | 7 | 10 |
| II | 4 | 6 |
| III | 24 | 31 |
| Disease status | ||
| Responsive | 12 | 19 |
| Refractory | 8 | 17 |
| Progressive | 15 | 11 |
| Median β-2 microglobulin (mg/L) (range) | 2.1 (0.3-8) | 1.9 (1.1-5.9) |
| Median C-reactive protein (mg/dL) (range) | 0.5 (0.1-3.4) | 0.9 (0.1-3.1) |
| Previous therapy | ||
| Alkylating agents | 20 | 26 |
| VAD + alkylating | 9 | 13 |
| VAD or VAD-like therapy | 15 | 20 |
| α-IFN + other | 3 | 3 |
| Median time from diagnosis to transplant in months (range) | 15 (6-78) | 13 (4-58) |
| Characteristics . | No. of patients . | |
|---|---|---|
| TX1 . | TX2 . | |
| Median age in years (range) | 51 (29-64) | 52 (32-60) |
| Sex (M/F) | 20/15 | 30/17 |
| Tumor stage | ||
| I | 7 | 10 |
| II | 4 | 6 |
| III | 24 | 31 |
| Disease status | ||
| Responsive | 12 | 19 |
| Refractory | 8 | 17 |
| Progressive | 15 | 11 |
| Median β-2 microglobulin (mg/L) (range) | 2.1 (0.3-8) | 1.9 (1.1-5.9) |
| Median C-reactive protein (mg/dL) (range) | 0.5 (0.1-3.4) | 0.9 (0.1-3.1) |
| Previous therapy | ||
| Alkylating agents | 20 | 26 |
| VAD + alkylating | 9 | 13 |
| VAD or VAD-like therapy | 15 | 20 |
| α-IFN + other | 3 | 3 |
| Median time from diagnosis to transplant in months (range) | 15 (6-78) | 13 (4-58) |
TX, treatment; VAD, vincristine, doxorubicin, and dexamethasone; IFN, interferon. Statistical analysis did not show any difference between the 2 series of patients. Thirty-one patients (TX1 = 13; TX2 = 18) were reinfused with highly purified CD34+ cells. When analyzed separately, we did not find any difference with patients receiving unmanipulated PBSC as for the major prognostic factors listed in the Table. Patients were staged according to Durie and Salmon classification.